Amanda M. Goceljak

• Bristol Myers Squibb in its multiprogram global strategic collaboration and license agreements with Hengrui Pharma to advance innovative medicines across oncology, hematology, and immunology, including a $600 million upfront payment, up to $350 million in anniversary payments, and up to $15.2 billion in total potential value
• Bristol Myers Squibb in its agreement with Bain Capital to create a new independent biopharmaceutical company focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients, including a $300 million investment by Bain Capital
• Bristol Myers Squibb in its global strategic partnership agreement, valued up to $11.1 billion, with BioNTech SE to co-develop and co-commercialize BNT327, a next-generation antibody targeting PD-L1 and VEGF for the treatment of multiple solid tumor types
• Alexion, AstraZeneca Rare Disease in connection with a series of strategic collaborations with JCR Pharmaceuticals, including to develop genomic medicine programs using JCR’s proprietary AAV capsids as well as programs to develop protein and oligonucleotide therapeutic molecules using JCR’s proprietary J-Brain Cargo® blood-brain barrier penetration technology
• Bristol Myers Squibb in its global exclusive license agreement, valued up to $1.35 billion, with BioArctic AB for BioArctic’s PyroGlutamate-amyloid-beta antibody program for Alzheimer’s disease
• MeiraGTX Holdings in its strategic transaction, valued at up to $415 million, to divest all rights in botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR), a rare disease gene therapy for the treatment of X-linked retinitis pigmentosa (XLRP), to Janssen Pharmaceuticals
• GlaxoSmithKline in a strategic transaction, valued up to $1 billion, among GSK, Arrowhead Pharmaceuticals, and Janssen Pharmaceuticals to acquire exclusive worldwide rights to further develop and commercialize a clinical-stage siRNA therapeutic (JNJ-3989, formerly ARO-HBV) for the treatment of chronic hepatitis B
• GlaxoSmithKline in its collaboration agreement, valued at up to $1.46 billion, with Mersana Therapeutics to co-develop and commercialize XMT-2056, an Immunosynthen antidrug conjugate targeting cancer
• Bristol Myers Squibb in its exclusive license agreement, valued up to $905 million, with BridgeBio Pharma, Inc. to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology
• GlaxoSmithKline in its exclusive license, valued at up to $1 billion, with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference therapeutic, which is currently being developed as a treatment for patients with NASH
• Gilead in its collaboration agreement with Scholar Rock Holding for the development and commercialization of Scholar Rock’s novel therapies for fibrotic diseases targeting latent TGF-beta1
• Incyte in its agreement with Foundation Medicine for the development, regulatory support and commercialization of companion diagnostics, with an initial focus on CDx development for Incyte’s selective FGFR1/2/3 inhibitor in patients with cholangiocarcinoma
• Regeneron in its agreement with bluebird bio to develop and commercialize new cell therapies for cancer. As part of the transaction, Regeneron made a $100 million investment in bluebird bio common stock
• Celgene in its licensing agreement with Amunix relating to Amunix’s XTEN and ProTIA technology to augment the discovery and development of therapeutic products
• Celgene in its drug-discovery collaboration with Cancer Research Technology (CRT), to discover, develop and commercialize new anti-cancer treatments centered on mRNA translation
• Shire in its agreement with Novimmune granting Shire exclusive worldwide rights to develop, manufacture and commercialize novel bispecific antibodies for the treatment of hemophilia A
• AstraZeneca in the co-development agreement between its subsidiary, Pearl Therapeutics, and Avillion for the global advancement of Pearl Therapeutics’ PT027, a treatment for asthma
• Merck KGaA in its clinical co-development agreement with Avillion to develop through Phase III Merck’s bi-specific anti IL-17 A/F Nanobody® for plaque psoriasis
• Regeneron in its licensing and collaboration agreement with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development, with Intellia receiving a $75 million upfront payment and potential milestone and royalties
• Teva in connection with its $40.5 billion acquisition of Allergan’s worldwide generic pharmaceutical business
• GSK in the sale of its rights to Prolia® (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) to Amgen
• Incyte in its license and collaboration agreement with Jiangsu Hengrui Medicine for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody, worldwide except mainland China, Hong Kong, Macau, and Taiwan
• Merck in the sale of its ophthalmics business
• GSK in the formation of the Altius Institute for Biomedical Sciences, an independent, non-profit research institute, in Seattle, Washington, to be led by Dr. John A. Stamatoyannopoulos
• Merck in its $14.2 billion agreement to sell its consumer care business to Bayer

Results may vary depending on your particular facts and legal circumstances.